Exane BNP Paribas Downgrades GlaxoSmithKline (GSK) to Underperform

September 13, 2016 12:56 PM EDT
Get Alerts GSK Hot Sheet
Price: $37.70 +0.72%

Rating Summary:
    6 Buy, 10 Hold, 3 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade GSK Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Exane BNP Paribas downgraded GlaxoSmithKline (NYSE: GSK) from Neutral to Underperform.

For an analyst ratings summary and ratings history on GlaxoSmithKline click here. For more ratings news on GlaxoSmithKline click here.

Shares of GlaxoSmithKline closed at $43.30 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Downgrades

Add Your Comment